<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958136</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2017-12</org_study_id>
    <nct_id>NCT03958136</nct_id>
  </id_info>
  <brief_title>Clinico-biological Data Collection Study of Metastatic Breast Cancer</brief_title>
  <acronym>EPICUREseinmet</acronym>
  <official_title>Prediction in Silico of Overall Survival in a Pilot Prospective Cohort Study of Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Regional Development Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment
      are poorly understood and are multifactorial. These mechanisms involve clinical and
      biological factors associated with the host and the tumor and possibly the patient's
      psycho-social environment.

      PURPOSE : This trial will assess the use of a prospective database dedicated to patients with
      breast cancers that contains clinical data as well as epidemiological, psychological,
      emotional, social, imaging, biological and bio-pathological data. These data will allow a
      creation of new modelling algorithms in order to predict response and resistance to
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study will be conducted on first line metastatic breast cancer patients.

      Three phenotypic groups are identified on immunohistochemistry done at inclusion: on
      metastatic sites or breast tumor if local recurrence, usual treatment protocols are often
      guided by the following groups:

        -  Group 1 : Patients HR (Hormon Receptor) + (E (Estrogen Receptor) + and/or PR
           (Progesterone Receptor) +) and HER2- (Human Epidermal Growth Factor Receptor-2)

        -  Group 2 : Patients HER2 + with or without HR+

        -  Group 3 : Patients triple negative (HR- and HER2-) Patients will receive treatments as
           per standard care according to the patient group.

      Standard treatments recommended for treatment first line are:

        1. For group 1 : For HR + and HER2- patients :

             -  For patients requiring Chemotherapy (visceral crisis), the recommended treatment is
                : Taxanes based chemotherapy Anthracyclines based chemotherapy

             -  For the patients without visceral crisis: the recommended treatment is : Hormonal
                therapy combined with CDK 4-6 inhibitors (Cyclin-dependent kinase) as recommended
                in standard care.

        2. For group 2 : HER2 + (with or without HR+), the recommended treatment is :

             -  Paclitaxel (Taxol) combined with Trastuzumab (Herceptin) and Pertuzumab (Perjeta)
                as per the institutional standard of care.

             -  Docetaxel (Taxotere) combined with Trastuzumab (Herceptin) and Pertuzumab (Perjeta)
                as per the institutional standard of care.

        3. For group 3 : triple negative (HR- and HER2-) patients, the recommended treatment is :

             -  Paclitaxel (Taxol) with or without Bevacizumab (Avastin) as per the institutional
                standard of care.

      Further treatment lines are administered according to standard practice. Biological and
      histological assessments are performed on specific metastasis biopsy samples done at baseline
      and at each progression.

      Physical exam, standard laboratory tests, imaging (CT (computerized tomography) scan, PET-CT
      (Positron emission tomography-computed tomography) and bone scan (for patients with bone
      metastasis) will be performed every 2 to 6 months according to patient group.

      Clinical, biological, pathological, epidemiological, socio-economic and multi-omic data will
      be collected throughout the study duration.

      These massive data will be used to create new algorithms in order to help clinicians to
      predict treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2034</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2033</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>monocentric, open, prospective database with specific biopsy and blod collections done (biocollection)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Creation of complex prospective clinico-biological database in metastatic breast cancer</measure>
    <time_frame>At each progressive disease, 15 years after inclusion</time_frame>
    <description>specific metastatic biopsy intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creation of complex prospective clinico-biological database in metastatic breast cancer</measure>
    <time_frame>At each progressive disease, 15 years after inclusion</time_frame>
    <description>search of algorithms combining multiple data (clinical, biological, imaging) in breast cancer management</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>15 years after inclusion</time_frame>
    <description>Overall Survival is the delay between the date of inclusion and the date of death or last follow-up assessment if censored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>15 years after inclusion</time_frame>
    <description>Progression Free survival is the delay between the first dose of a treatment sequence and the date of documented disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during treatment</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>QLQ-C30 Questionnaire (total score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during treatment</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>BR23 Questionnaire (total score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during treatment</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>STAI anxiety Questionnaire (total score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during treatment</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>Beck Depression Inventory (BDI) (total score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment for each therapeutic sequence</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>RECIST 1.1 or iRECIST assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment for each therapeutic sequence</measure>
    <time_frame>every 4-6 months for 15 years after inclusion</time_frame>
    <description>biological assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients HR + and HER2-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :
Metastasis biopsy
Biomarkers blood, urine and microbiota samples
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients HER2 + with or without HR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :
Metastasis biopsy
Biomarkers blood, urine and microbiota samples
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients triple negative (HR- and HER2-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At each disease progression, patient will have specific interventions :
Metastasis biopsy
Biomarkers blood, urine and microbiota samples
Patient Reported Outcome (PRO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Metastasis biopsy</intervention_name>
    <description>Metastasis biopsy will be performed for multi-omic analysis</description>
    <arm_group_label>Patients HER2 + with or without HR+</arm_group_label>
    <arm_group_label>Patients HR + and HER2-</arm_group_label>
    <arm_group_label>Patients triple negative (HR- and HER2-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biomarkers blood, urine and microbiota samples</intervention_name>
    <description>Biomarkers blood, urine and microbiota samples for multi-omic analysis</description>
    <arm_group_label>Patients HER2 + with or without HR+</arm_group_label>
    <arm_group_label>Patients HR + and HER2-</arm_group_label>
    <arm_group_label>Patients triple negative (HR- and HER2-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient Reported Outcome (PRO)</intervention_name>
    <description>Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.</description>
    <arm_group_label>Patients HER2 + with or without HR+</arm_group_label>
    <arm_group_label>Patients HR + and HER2-</arm_group_label>
    <arm_group_label>Patients triple negative (HR- and HER2-)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained from the patient prior to performing any
             protocol-related procedures, including screening biopsy, blood sample, faeces and
             questionnaires

          2. Women &gt; 18 years old at time of written consent

          3. Patient with histologically confirmed breast cancer

          4. Breast cancer metastatic disease or locally advanced not eligible for local curative
             treatment intent with or without personal history of adjuvant therapy for this cancer
             (chemotherapy, radiotherapy, surgery …)

          5. Patient with metastases that can be biopsied.

          6. Performance status ≤ 2 (according to WHO criteria)

          7. Indication of any systemic therapeutic strategy can be performed alongside this
             current cohort in accordance with national and / or international recommendations.

          8. HR and HER2 status on metastatic sites or breast tumor if local recurrence:

               -  For group 1 :

                    -  Histologic and/or cytological confirmation of estrogen-receptor positive
                       (ER+) and/ or progesterone receptor positive (PR+) breast cancer determined
                       by local laboratory testing

                    -  No HER2-overexpression in the patient's tumor tissue determined by local
                       laboratory testing

               -  For group 2 :

                    -  Histologic and/or cytological confirmation of estrogen-receptor positive or
                       negative and/ or progesterone receptor positive or negative breast cancer
                       determined by local laboratory testing

                    -  HER2-overexpression in the patient's tumor tissue determined by local
                       laboratory testing

               -  For group 3 :

                    -  Histologic and/or cytological confirmation of estrogen-receptor negative and
                       progesterone receptor negative breast cancer determined by local laboratory
                       testing

                    -  No HER2-overexpression in the patient's tumor tissue determined by local
                       laboratory testing

          9. Menopausal status : as per the institutional standard of care

         10. Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

         11. Patient must be affiliated to a Social Health Insurance

        Exclusion Criteria:

          1. Other malignancy treated within the last 5 years (except non-melanoma skin cancer or
             in situ carcinoma of the cervix)

          2. Coagulopathy or other pathology that contraindicates biopsy procedures

          3. Prior systemic treatment in metastatic setting

          4. Patients with exclusive brain metastasis not available for surgery

          5. Pregnant or nursing patient

          6. Individual deprived of liberty or placed under the authority of a tutor

          7. Impossibility to submit to the medical follow-up of this clinical trial for
             geographical, social or psychological reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario CAMPONE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario CAMPONE, MD, PhD</last_name>
    <phone>+33240679900</phone>
    <phone_ext>9510</phone_ext>
    <email>mario.campone@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marine TIGREAT</last_name>
    <phone>+33240679900</phone>
    <phone_ext>9878</phone_ext>
    <email>marine.tigreat@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cacerologie de l'ouest - site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario CAMPONE, MD, PhD</last_name>
      <phone>+33240679900</phone>
      <phone_ext>9510</phone_ext>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario CAMPONE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne PATSOURIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline FONSEGRIVE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elouen BOUGHALEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic BIGOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie VANBOCKSTAEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paule AUGEREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick SOULIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie ABADIE LACOURTOISIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario CAMPONE, MD, PhD</last_name>
      <phone>+33240679900</phone>
      <phone_ext>9510</phone_ext>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario CAMPONE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Sebastien FRENEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique BERTON-RIGAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle BOURBOULOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ROBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole GOURMELON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline DU RUSQUEC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 31, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>first metastatic setting</keyword>
  <keyword>prospective clinico-biological database</keyword>
  <keyword>multi omic analysis</keyword>
  <keyword>prediction in silico</keyword>
  <keyword>overall survival</keyword>
  <keyword>progression free survival</keyword>
  <keyword>predictive factors</keyword>
  <keyword>treatment response</keyword>
  <keyword>resistance to cancer therapy</keyword>
  <keyword>socio demographic profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

